Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Beijing Biotech
Avera McKennan Hospital & University Health Center
National Institutes of Health Clinical Center (CC)
Filamon LTD
AstraZeneca
Hoffmann-La Roche
Cancer Research UK
Children's Oncology Group
Essen Biotech
Essen Biotech
xCures
University of Nebraska
Adela, Inc
Dysplasia Diagnostics Limited
Mayo Clinic
Degron Therapeutics Co.
University of Southern California
University Health Network, Toronto
Cancer Research UK
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Massive Bio, Inc.
Incyte Corporation
Hadassah Medical Organization
AVM Biotechnology Inc
LigaChem Biosciences, Inc.
Washington University School of Medicine
Incyte Corporation
Jonsson Comprehensive Cancer Center
Tempus AI
University of South Florida
Stanford University
Universidade Federal de Pernambuco
Aminex Therapeutics, Inc.
Taproot Health
VitaMed Research LLC
Washington University School of Medicine
NGM Biopharmaceuticals, Inc
Mayo Clinic
ABM Therapeutics Corporation
Memorial Sloan Kettering Cancer Center
UNICANCER
Sumitomo Pharma America, Inc.
Children's Oncology Group
Kaohsiung Medical University Chung-Ho Memorial Hospital
Hoffmann-La Roche
City of Hope Medical Center
Eastern Cooperative Oncology Group
KIYATEC